PNC-27
Investigación emergenteAnti-Cancer Peptide | p53-HDM-2 Disruptor
PNC-27 is an experimental anti-cancer peptide created by a supercomputer at SUNY Downstate Medical Center in 2000.
Datos moleculares y de investigación
- Peso molecular
- ~3,500 Da
- Vida media
- Less than 24 hours (requires daily dosing in studies)
- Rutas (investigación)
- injectable
- Almacenamiento
- Refrigerate at 2-8°C
Overview
PNC-27 is an experimental anti-cancer peptide created by a supercomputer at SUNY Downstate Medical Center in 2000. It contains an HDM-2 binding domain from p53 (residues 12-26) linked to a cell-penetrating domain. The peptide selectively kills cancer cells by binding to HDM-2 (MDM2) expressed on cancer cell membranes, forming pores that cause cell necrosis. Critically, PNC-27 has no effect on normal cells because healthy cells don’t express HDM-2 on their membranes. Research shows effectiveness against pancreatic cancer, breast cancer, leukemia, and melanoma.
Mechanism of action
PNC-27 exploits a unique vulnerability of cancer cells: the presence of HDM-2 (human double minute 2, also called MDM2) on their cell surface. The peptide’s p53 residues adopt a conformation that binds directly to membrane-bound HDM-2, inducing transmembrane pore formation. This causes rapid tumor cell necrosis (not apoptosis). Additionally, PNC-27 enters cancer cells and disrupts mitochondrial membranes. Normal cells lack surface HDM-2 expression and are completely spared.
Key research findings
- Selectively kills cancer cells only
- No effect on normal healthy cells
- Induces rapid cancer cell necrosis
- Works on multiple cancer types
- Unique membrane pore mechanism
- Does not require p53 function in target cells
- Eradicates tumors in mouse models
- Spares human stem cells
Research applications
Cancer Research
- Pancreatic Cancer — PNC-27 shows selective cytotoxicity against pancreatic cancer cells in research.
- Breast Cancer — Demonstrated effectiveness against breast cancer cell lines.
- Leukemia — Induces necrosis of K-562 leukemia cells through HDM-2 binding.
- Melanoma — Shows selective targeting of melanoma cells.
Mechanism Studies
- HDM-2 Expressing Tumors — Most effective against cancers with high membrane HDM-2 expression.
- Tumor Selectivity Research — Model compound for studying cancer-selective therapies.
Preguntas frecuentes sobre PNC-27
Why is PNC-27 described as 'cancer cell-selective' when normal cells can express HDM-2?+
The key difference is location. Normal cells express HDM-2 intracellularly, not on their cell surface. PNC-27 requires membrane-bound HDM-2 to form pores. Cancer cells uniquely express HDM-2 on their plasma membrane, making them susceptible to attack while normal cells are completely spared. This surface expression is a cancer-specific vulnerability.
Is PNC-27 closer to clinical trials than other peptide cancer therapies?+
Not yet. PNC-27 remains in preclinical research with no human clinical trials initiated as of 2025. While it's been studied since 2000, it hasn't progressed to human testing. That's partly because cancer drug development is slow and partly because peptide therapeutics face delivery challenges that are being actively researched.
Why would someone take PNC-27 if it doesn't prevent cancer recurrence?+
PNC-27 is purely experimental—it eradicates tumor cells in mouse models through a unique mechanism (membrane pore formation + mitochondrial damage). Once human trials exist (which they don't yet), the intent would be cancer treatment, not prevention. Until then, it's a research tool for understanding cancer-selective therapies.
Could PNC-27 work on cancers that don't express HDM-2?+
No. PNC-27's entire mechanism depends on membrane HDM-2 binding. Cancers without membrane HDM-2 expression wouldn't respond. This is both a strength (high selectivity) and a limitation (requires the right cancer type). Assessing HDM-2 status would be critical before attempting any therapeutic use.
References
- [1]Anticancer peptide PNC-27 adopts an HDM-2-binding conformation and kills cancer cells by binding to HDM-2 in their membranesPNAS
- [2]Anti-Cancer Peptide PNC-27 Kills Cancer Cells by Unique Interactions with Plasma Membrane-Bound hdm-2 and with Mitochondrial MembranesPubMed
- [3]PNC-27 Induces Tumor Cell Necrosis of Leukemia CellsAnnals of Clinical & Laboratory Science
- [4]PNC-27, a Chimeric p53-Penetratin PeptidePubMed
Péptidos relacionados
5-Amino-1MQ
PreclinicalNNMT Inhibitor | Longevity & Metabolic Enhancement
5-Amino-1MQ is a small molecule NNMT (nicotinamide N-methyltransferase) inhibitor that enhances cellular NAD+ levels and mitochondrial function.
Adalank
Emerging researchN-Acetyl Selank Amidate | Enhanced Tuftsin Analog
Enhanced derivative of Selank with improved stability, blood-brain barrier penetration, and extended half-life compared to parent compound. Parent compound Selank approved in Russia since early 2000s.
Adamax
Emerging researchNext-Generation Semax Derivative | Nootropic Neuropeptide
Synthetic nootropic peptide with N-terminal acetylation and C-terminal adamantane modification for superior stability and blood-brain barrier penetration, researched for cognitive enhancement,
Cardiogen
Moderate researchAEDR | Cardiovascular Bioregulator Peptide
Cardiogen is a Khavinson bioregulator peptide consisting of four amino acids, derived from heart tissue research.